130447-37-9

Basic information

• Product Name: 1,25-dihydroxy-19-norvitamin D3
• Synonyms: 1,25-dihydroxy-19-norvitamin D3;19-Norcalcitrol;Ro 27-5256;(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
• CAS NO: 130447-37-9
• Molecular Formula: C₂₆H₄₄O₃
• Molecular Weight: 404.62576
• Mol File: 130447-37-9.mol

Chemical Properties

• Boiling Point: 552°C at 760 mmHg
• Flash Point: 234.1°C
• Appearance: /
• Density: 1.121g/cm³
• Vapor Pressure: 1.74E-14mmHg at 25°C
• Refractive Index: 1.603
• PKA: 14.34±0.40(Predicted)
• CAS DataBase Reference: 1,25-dihydroxy-19-norvitamin D3(CAS DataBase Reference)
• NIST Chemistry Reference: 1,25-dihydroxy-19-norvitamin D3(130447-37-9)
• EPA Substance Registry System: 1,25-dihydroxy-19-norvitamin D3(130447-37-9)

Safety Data

• Hazardous Substances Data: 130447-37-9(Hazardous Substances Data)

Usage

Type

Synthetic form of vitamin D3

Modification

Lacks a carbon atom at the 19th position

Receptor

Potent agonist of the vitamin D receptor

Biological activity

Similar to natural 1,25-dihydroxyvitamin D3

Therapeutic uses

Studied for potential applications in osteoporosis, cancer, and autoimmune disorders

Role in metabolism

Investigated for its regulation of calcium and phosphorus metabolism

Effects on the immune system

Investigated for its impact on the immune system and inflammation

Applications

Promising compound with potential applications in various areas of medicine and physiology

InChI:InChI=1/C26H44O3/c1-18(7-5-13-25(2,3)29)23-11-12-24-20(8-6-14-26(23,24)4)10-9-19-15-21(27)17-22(28)16-19/h9-10,18,21-24,27-29H,5-8,11-17H2,1-4H3/b20-10+/t18-,21+,22+,23-,24+,26-/m1/s1

Upstream product

• 130447-33-5 10-oxo-1α,25-dihydroxycyclovitamin D3 
• 130447-38-0 Acetic acid (1S,3S,5S)-2-hydroxy-1-{(R)-2-[(3aS,7aR)-1-((R)-5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-1-methoxy-ethyl}-2-hydroxymethyl-bicyclo[3.1.0]hex-3-yl ester 
• 141839-53-4 Acetic acid (1S,3S,5S)-1-{(R)-2-[(3aS,7aR)-1-((R)-5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-1-methoxy-ethyl}-2-methanesulfonyloxy-bicyclo[3.1.0]hex-3-yl ester 
• 77-95-2 D-(-)-quinic acid 
• 191916-39-9 methyl (-)-quinate 
• 139356-34-6 (3S,5S)-3,5-bis[tert-butyl(dimethyl)silyloxy]-1-(hydroxylmethyl)cyclohexanol 
• 139356-37-9 [(3R,5R)-3,5-bis-(tert-butyldimethylsilanyloxy)cyclohexylidene]-ethanol 
• 139356-38-0 ((1R,3R)-5-(2-chloroethylidene)cyclohexane-1,3-diyl)bis(oxy)bis(tert-butyldimethylsilane) 
• 139356-33-5 (3S,5S)-3,5-bis[(tert-butyl)dimethylsilyloxy]-1-hydroxycyclohexane-1-carboxylic acid methyl ester 
• 130447-34-6 Acetic acid (1R,3S,5S)-2-hydroxy-1-{(R)-2-[(3aS,7aR)-1-((R)-5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-1-methoxy-ethyl}-bicyclo[3.1.0]hex-3-yl ester 
• 74041-14-8 1α-acetoxy-25-hydroxy-3,5-cyclovitamin D3 
• 69662-74-4 25-hydroxyvitamin D₃ 
• 139356-40-4 (1R,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-cyclohexylidene]-eth-(E)-ylidene]-1-((R)-1,5-dimethyl-5-trimethylsilanyloxy-hexyl)-7a-methyl-octahydro-indene 
• 139356-39-1 (1R,3R)-1,3-bis((tert-butyldimethyl)silanyloxy)-5-[2-(diphenylphosphinoyl)-ethylidene]cyclohexane 

Relevant articles and documents

1α,25-dihydroxy-19-nor-vitamin D3, a novel vitamin D-related compound with potential therapeutic activity

1α,25-Dihydroxy-19-nor-vitamin D3 has been synthesized via oxidative degradation of the 1α-hydroxycylcovitamin intermediate. Preliminary studies indicate that the new analog induces the differentiation of human leukemia HL-60 cells, with little or no calcemic activity. (Chemical Equation Presented).

Novel synthesis of 19-nor-vitamin D compounds

1α,25-Dihydroxy-19-nor-vitamin D3 was prepared efficiently in a convergent synthesis starting with (-)-quinic acid and a ketone of the Windaus-Grundmann type.